PUBLIC COMPANY
save$OLMAOlema Pharmaceuticals, Inc.
$OLMA11.94-0.91%San Francisco, CA, USupdated 17h ago
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 11Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- phase3OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- phase1A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
- phase1Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
- phase1Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- phase2A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (4)
- Mar 4, 26option exerciseMitchell Shawnte · CHIEF LEGAL OFFICER25,000 sh
- Mar 4, 26option exerciseMitchell Shawnte · CHIEF LEGAL OFFICER25,000 sh
- Mar 3, 26option exerciseMitchell Shawnte · CHIEF LEGAL OFFICER15,000 sh
- Mar 3, 26option exerciseMitchell Shawnte · CHIEF LEGAL OFFICER15,000 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that